4
Changes in Ownership
Immunome Inc. Filed Acc 0001994071-26-000002
Chief Financial Officer sold 65,000 shares at an average $21.92 ($1,424,916)
- Chief Financial Officer acquired 71,561 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Rosett Max Chief Financial Officer | 2026-04-02 | Option exercise 10b5-1 | +31,848 | $1.05 | $33,440 | 79,324 | D: show line 1 in the form |
| Rosett Max Chief Financial Officer | 2026-04-02 | Option exercise 10b5-1 | +39,713 | $1.35 | $53,613 | 119,037 | D: show line 2 in the form |
| Rosett Max Chief Financial Officer | 2026-04-02 | Sale 10b5-1 | −63,656 | $21.91 | $1,394,703 | 55,381 | D: show line 3 in the form |
| Rosett Max Chief Financial Officer | 2026-04-02 | Sale 10b5-1 | −1,344 | $22.48 | $30,213 | 54,037 | D: show line 4 in the form |
| Open-market sales · 65,000 sh · avg $21.92 · $1,424,916 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Rosett Max Chief Financial Officer | 2026-04-02 | Option exercise · Stock option (right to buy) 10b5-1 | −31,848 | 60,000 | D: show line 5 in the form | ||
| Rosett Max Chief Financial Officer | 2026-04-02 | Option exercise · Stock option (right to buy) 10b5-1 | −39,713 | 0 | D: show line 6 in the form |
Loading xslF345X06/form4-04032026_110446.xml…